Compare HBCP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | ARMP |
|---|---|---|
| Founded | 1908 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 383.7M |
| IPO Year | 2008 | 1996 |
| Metric | HBCP | ARMP |
|---|---|---|
| Price | $60.88 | $8.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $63.50 | $15.00 |
| AVG Volume (30 Days) | ★ 81.5K | 40.8K |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 29.01 | ★ 53.40 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $10.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.10 | $0.90 |
| 52 Week High | $64.17 | $13.75 |
| Indicator | HBCP | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 39.00 |
| Support Level | $56.27 | $5.14 |
| Resistance Level | $61.18 | $8.40 |
| Average True Range (ATR) | 1.78 | 0.92 |
| MACD | 0.16 | -0.48 |
| Stochastic Oscillator | 76.76 | 17.61 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.